S-3087-119
Read twice and referred to the Committee on the Judiciary.
Sponsored by Chuck Grassley (R-IA)
What it does
This bill would expand existing criminal penalties — currently applied to methamphetamine-related offenses — to also cover the possession, manufacture, or distribution of equipment and materials used to illegally produce fentanyl, fentanyl analogues, or counterfeit substances. It would require the Drug Enforcement Administration (DEA) to develop and implement a plan to combat counterfeit fentanyl and methamphetamine through law enforcement, education, and prevention. It would also require the Department of Justice (DOJ) to submit annual reports to Congress on law enforcement collection of counterfeit fentanyl and methamphetamine and related prosecutions.
Who benefits
Communities heavily affected by fentanyl overdoses, particularly those in regions with high rates of illicit drug trafficking. Family members and loved ones of people who use drugs, who may see reduced availability of counterfeit pills. Emergency responders and healthcare workers who treat overdose patients. Law enforcement agencies, which would gain clearer statutory authority and additional tools to prosecute fentanyl-related manufacturing. Policymakers and the public, who would gain more data through the new DOJ annual reporting requirement.
Who is hurt
Individuals convicted under the expanded penalty provisions, who would face longer sentences — including those who may play minor roles in manufacturing operations. Public defenders and the federal court system, which could face increased caseloads. Taxpayers, who would bear the cost of increased federal prosecutions and potential incarceration. Harm reduction advocates and organizations, who may argue that criminalization-focused approaches divert resources from treatment. People who use drugs and are in possession of equipment that could be characterized as manufacturing-related, who may face heightened prosecution risk.
Supporters argue
Supporters argue that fentanyl and counterfeit pills are driving a historic overdose crisis — the CDC reported over 74,000 synthetic opioid-involved deaths in a single recent year — and that existing penalties designed for methamphetamine manufacturing equipment are directly applicable to the fentanyl supply chain. They contend that expanding these penalties closes a legal gap that allows fentanyl precursor equipment to go unpunished at the same level as comparable methamphetamine equipment, and that the DEA planning and DOJ reporting requirements create accountability mechanisms to measure whether enforcement efforts are actually reducing the supply of counterfeit pills.
Opponents argue
Opponents argue that decades of research on mandatory and enhanced drug penalties — including the experience with crack cocaine sentencing enhancements — show that increased criminal penalties do not reliably reduce drug supply or use, and that this bill repeats a punitive approach with limited evidence of effectiveness. They contend that the bill's expansion of penalties to equipment possession could ensnare low-level or peripheral actors rather than major traffickers, and that federal resources would produce greater public health impact if directed toward treatment, naloxone distribution, and harm reduction programs rather than additional prosecutions.
Constitutional context
Congress has broad authority to regulate controlled substances and their manufacture under the Commerce Clause, and the existing Controlled Substances Act has been consistently upheld on that basis. The Eighth Amendment's proportionality principle is relevant to enhanced mandatory penalties — while the Supreme Court has not struck down drug manufacturing penalties of this type, Timbs v. Indiana (2019) reinforced that excessive punishment protections apply broadly, and any mandatory minimums embedded in the expanded penalties could face proportionality challenges.
Checks and balances
The executive branch (DEA and DOJ) gains expanded enforcement authority and new planning and reporting mandates; Congress retains oversight through the annual DOJ reporting requirement, and federal courts serve as a check through sentencing review and any constitutional challenges to penalty proportionality.
Historical precedent
The Combat Methamphetamine Epidemic Act of 2005 similarly expanded federal penalties and enforcement tools targeting methamphetamine manufacturing equipment and precursor chemicals, providing a direct structural analogue to this bill's approach.